DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
SEVIRUMAB
2
Antibody
Investigational
Unknown
Unknown
Cytomegalovirus Infections; Cytomegalovirus Retinitis
Envelope glycoprotein H inhibitor
SEVIRUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-54175446
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder, Major
P2X purinoceptor 7 antagonist
JNJ-54175446
×
Maximum Phase:
2
First Approval:
None
UNII:
32524GLF40
Molecule Type:
Small molecule
Molecular Formula:
C18H13ClF4N6O
Molecular Weight:
440.79
AlogP:
3.63
PSA:
76.8
HBD:
0.0
HBA:
#RotB:
2.0
Source:
FGFR INHIBITOR DEBIO 1347
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms; Neoplasms
Fibroblast growth factor receptor 1 inhibitor
FGFR INHIBITOR DEBIO 1347
×
Maximum Phase:
2
First Approval:
None
UNII:
NR9ZYH80Z8
Molecule Type:
Small molecule
Molecular Formula:
C20H16N6O
Molecular Weight:
356.39
AlogP:
3.35
PSA:
105.38
HBD:
3.0
HBA:
#RotB:
3.0
Source:
MASUPIRDINE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Unknown
MASUPIRDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
8XZ281AO3G
Molecule Type:
Small molecule
Molecular Formula:
C21H24BrN3O3S
Molecular Weight:
478.41
AlogP:
3.4
PSA:
54.78
HBD:
0.0
HBA:
#RotB:
5.0
Source:
PYRAZOLOACRIDINE
2
Small molecule
Investigational
Unknown
Unknown
Neuroblastoma; Breast Neoplasms; Central Nervous System Neoplasms; Lung Neoplasms; Melanoma
Unknown
PYRAZOLOACRIDINE
×
Maximum Phase:
2
First Approval:
None
UNII:
L24XJN68OW
Molecule Type:
Small molecule
Molecular Formula:
C19H21N5O3
Molecular Weight:
367.41
AlogP:
3.63
PSA:
85.46
HBD:
1.0
HBA:
#RotB:
6.0
Source:
MK-3577
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor antagonist
MK-3577
×
Maximum Phase:
2
First Approval:
None
UNII:
03TW1410NL
Molecule Type:
Small molecule
Molecular Formula:
C30H30ClFN2O3
Molecular Weight:
521.03
AlogP:
7.19
PSA:
82.19
HBD:
3.0
HBA:
#RotB:
10.0
Source:
TEBANICLINE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TEBANICLINE
×
Maximum Phase:
2
First Approval:
None
UNII:
9KX8NKV538
Molecule Type:
Small molecule
Molecular Formula:
C9H11ClN2O
Molecular Weight:
198.65
AlogP:
1.48
PSA:
34.15
HBD:
1.0
HBA:
#RotB:
3.0
Source:
EPETRABOROLE
2
Small molecule
Investigational
Unknown
Unknown
Infections
Leucine--tRNA ligase inhibitor
EPETRABOROLE
×
Maximum Phase:
2
First Approval:
None
UNII:
6MC93Z2DF9
Molecule Type:
Small molecule
Molecular Formula:
C11H16BNO4
Molecular Weight:
237.06
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
PITRAKINRA
2
Protein
Investigational
Unknown
Unknown
Asthma; Dermatitis, Atopic
Unknown
PITRAKINRA
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-49095397
2
Small molecule
Investigational
Unknown
Unknown
Respiratory Syncytial Virus Infections; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic, Seasonal
Unknown
JNJ-49095397
×
Maximum Phase:
2
First Approval:
None
UNII:
I92MU0V408
Molecule Type:
Small molecule
Molecular Formula:
C34H36N6O4
Molecular Weight:
592.7
AlogP:
6.83
PSA:
119.4
HBD:
3.0
HBA:
#RotB:
9.0
Source:
OGX-427
2
Oligonucleotide
Investigational
Unknown
Unknown
Unknown
Unknown
OGX-427
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Oligonucleotide
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACP-001
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ACP-001
×
Maximum Phase:
2
First Approval:
None
UNII:
5377795HRF
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Large B-Cell, Diffuse; Leukemia, Biphenotypic, Acute; Lymphoma, Follicular
CD22 inhibitor
YTTRIUM Y 90 EPRATUZUMAB TETRAXETAN
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAB-3F8
2
Antibody
Investigational
Unknown
Unknown
Neuroblastoma
Disialoganglioside GD2 binding agent
MAB-3F8
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LORVOTUZUMAB MERTANSINE
2
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Small Cell Lung Carcinoma; Leukemia; Neurilemmoma; Neuroblastoma; Rhabdomyosarcoma; Sarcoma, Synovial; Wilms Tumor
Neural cell adhesion molecule 1 binding agent
LORVOTUZUMAB MERTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
0IVD6ASY0W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMCASERTIB
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cholangiocarcinoma; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Urinary Bladder Neoplasms
Unknown
AMCASERTIB
×
Maximum Phase:
2
First Approval:
None
UNII:
GLY8ABW25V
Molecule Type:
Small molecule
Molecular Formula:
C31H33N5O2S
Molecular Weight:
539.71
AlogP:
5.99
PSA:
90.12
HBD:
3.0
HBA:
#RotB:
9.0
Source:
TETRADECYLTHIOACETIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TETRADECYLTHIOACETIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
7ZU5I25S2O
Molecule Type:
Small molecule
Molecular Formula:
C16H32O2S
Molecular Weight:
288.5
AlogP:
5.51
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
15.0
Source:
PUERARIN
2
Small molecule
Investigational
Unknown
Unknown
Alcoholism; Arthritis, Rheumatoid; Cardiovascular Diseases
Unknown
PUERARIN
×
Maximum Phase:
2
First Approval:
None
UNII:
Z9W8997416
Molecule Type:
Small molecule
Molecular Formula:
C21H20O9
Molecular Weight:
416.38
AlogP:
0.39
PSA:
160.82
HBD:
6.0
HBA:
#RotB:
3.0
Source:
MK-0893
2
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Glucagon receptor antagonist
MK-0893
×
Maximum Phase:
2
First Approval:
None
UNII:
CCP2U6LWTP
Molecule Type:
Small molecule
Molecular Formula:
C32H27Cl2N3O4
Molecular Weight:
588.49
AlogP:
7.5
PSA:
93.45
HBD:
2.0
HBA:
#RotB:
9.0
Source:
SF-1126
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Neuroblastoma; Carcinoma, Squamous Cell
PI3-kinase class I inhibitor
SF-1126
×
Maximum Phase:
2
First Approval:
None
UNII:
DL0Q912033
Molecule Type:
Small molecule
Molecular Formula:
C39H48N8O14
Molecular Weight:
852.86
AlogP:
-2.87
PSA:
341.7
HBD:
9.0
HBA:
#RotB:
22.0
Source:
TB-402
2
Antibody
Investigational
Unknown
Unknown
Venous Thromboembolism
Coagulation factor VIII inhibitor
TB-402
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MYO-029
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MYO-029
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATN-161
2
Protein
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Carcinoma, Renal Cell
Integrin alpha-5/beta-1 antagonist
ATN-161
×
Maximum Phase:
2
First Approval:
None
UNII:
XW0H5LE42K
Molecule Type:
Protein
Molecular Formula:
C23H35N9O8S
Molecular Weight:
597.66
AlogP:
-4.81
PSA:
271.8
HBD:
9.0
HBA:
#RotB:
15.0
Source:
ARQ 087
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ARQ 087
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAGOPILONE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Glioblastoma; Melanoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma
Tubulin stabiliser
SAGOPILONE
×
Maximum Phase:
2
First Approval:
None
UNII:
KY72JU32FO
Molecule Type:
Small molecule
Molecular Formula:
C30H41NO6S
Molecular Weight:
543.73
AlogP:
5.46
PSA:
109.25
HBD:
2.0
HBA:
#RotB:
3.0
Source:
AZM-475271
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Tyrosine-protein kinase ABL inhibitor
AZM-475271
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PYRIDOXAMINE
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Kidney Calculi
Unknown
PYRIDOXAMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
6466NM3W93
Molecule Type:
Small molecule
Molecular Formula:
C8H12N2O2
Molecular Weight:
168.2
AlogP:
0.05
PSA:
79.37
HBD:
3.0
HBA:
#RotB:
2.0
Source:
PASCOLIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma; Tuberculosis
Interleukin-4 inhibitor
PASCOLIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
N1IOA09R6A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OPEBACAN
2
Protein
Investigational
Unknown
Unknown
Graft vs Host Disease
Lipopolysaccharide (LPS) sequestering agent
OPEBACAN
×
Maximum Phase:
2
First Approval:
None
UNII:
4X9EPQ6FMA
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MITOQUINONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
MITOQUINONE
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SYNTHETIC PREIMPLANTATION FACTOR
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
SYNTHETIC PREIMPLANTATION FACTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PRX-321
2
Unknown
Investigational
Unknown
Unknown
Glioblastoma
Unknown
PRX-321
×
Maximum Phase:
2
First Approval:
None
UNII:
FRY3MOL2QU
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NASTORAZEPIDE CALCIUM
2
Unknown
Investigational
Unknown
Unknown
Pancreatic Neoplasms
Unknown
NASTORAZEPIDE CALCIUM
×
Maximum Phase:
2
First Approval:
None
UNII:
GZ3I1DMI8Q
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARBUTIN
2
Small molecule
Investigational
Unknown
Unknown
Melanosis
Tyrosinase inhibitor
ARBUTIN
×
Maximum Phase:
2
First Approval:
None
UNII:
C5INA23HXF
Molecule Type:
Small molecule
Molecular Formula:
C12H16O7
Molecular Weight:
272.25
AlogP:
-1.43
PSA:
119.61
HBD:
5.0
HBA:
#RotB:
3.0
Source:
CT-2584
2
Small molecule
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Unknown
CT-2584
×
Maximum Phase:
2
First Approval:
None
UNII:
67E5N3R22H
Molecule Type:
Small molecule
Molecular Formula:
C30H55N5O3
Molecular Weight:
533.8
AlogP:
5.43
PSA:
94.08
HBD:
2.0
HBA:
#RotB:
23.0
Source:
1
2
…
200
201
202
203
204
205
206
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA